PMID- 30652502
OWN - NLM
STAT- MEDLINE
DCOM- 20190207
LR  - 20220816
IS  - 1751-2441 (Electronic)
IS  - 1751-2433 (Linking)
VI  - 12
IP  - 2
DP  - 2019 Feb
TI  - A meta-analysis of naldemedine for the treatment of opioid-induced constipation.
PG  - 121-128
LID - 10.1080/17512433.2019.1570845 [doi]
AB  - Opioid-induced constipation (OIC) is a common adverse effect in patients under 
      long-term opioid therapy. Naldemedine is a novel peripherally acting mu-opioid 
      receptor antagonists being developed for the treatment of OIC without affecting 
      central analgesia. This meta-analysis is to assess the current evidence for 
      efficacy and safety of naldemedine for the treatment of OIC. Areas covered: We 
      searched through MEDLINE, EMBASE, Web of Science and Cochrane Library, 'ISRCTN 
      Register' and'ClinicalTrials.gov' (up to Aug 2018). Our final review included 
      five randomized clinical trials (1751 participants in total), three trials 
      observed naldemedine for the treatment of OIC in non-cancer patients and two 
      trials in cancer patients. A Random Effects model was used for all comparisons. 
      Subgroup analyses for the following subgroups were carried out: naldemedine 0.1 
      mg; 0.2 mg; 0.4 mg; cancer patients; non-cancer patients. Expert opinion: 
      Naldemedine improved the proportion of responders and spontaneous bowel movements 
      frequency. The incidence of serious adverse effects (AEs) in naldemedine group 
      was higher than placebo, especially in cancer patient subgroup. The AEs occurred 
      in participants with naldemedine were mild to moderate and well tolerated during 
      treatment. The results of this network meta-analysis will guide the future 
      researchers in evaluating naldemedine for the treatment of OIC.
FAU - Song, Xuesong
AU  - Song X
AD  - a Department of Anesthesiology , the First Hospital of Jilin University , 
      Changchun , China.
FAU - Wang, Dunwei
AU  - Wang D
AD  - a Department of Anesthesiology , the First Hospital of Jilin University , 
      Changchun , China.
FAU - Qu, Xiaoyu
AU  - Qu X
AUID- ORCID: 0000-0003-1685-6914
AD  - b Department of Pharmacy , the First Hospital of Jilin University , Changchun , 
      China.
FAU - Dong, Naifu
AU  - Dong N
AD  - a Department of Anesthesiology , the First Hospital of Jilin University , 
      Changchun , China.
FAU - Teng, Shiyong
AU  - Teng S
AD  - a Department of Anesthesiology , the First Hospital of Jilin University , 
      Changchun , China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
DEP - 20190124
PL  - England
TA  - Expert Rev Clin Pharmacol
JT  - Expert review of clinical pharmacology
JID - 101278296
RN  - 0 (Analgesics, Opioid)
RN  - 0 (Narcotic Antagonists)
RN  - 0 (Receptors, Opioid, mu)
RN  - 03KSI6WLXH (naldemedine)
RN  - 5S6W795CQM (Naltrexone)
SB  - IM
MH  - Analgesics, Opioid/administration & dosage/*adverse effects
MH  - Constipation/chemically induced/*drug therapy
MH  - Dose-Response Relationship, Drug
MH  - Humans
MH  - Naltrexone/administration & dosage/adverse effects/*analogs & 
      derivatives/pharmacology
MH  - Narcotic Antagonists/*administration & dosage/adverse effects/pharmacology
MH  - Randomized Controlled Trials as Topic
MH  - Receptors, Opioid, mu/antagonists & inhibitors
OTO - NOTNLM
OT  - Meta-analysis
OT  - chronic severe pain
OT  - efficacy
OT  - naldemedine
OT  - opioid-induced constipation
OT  - safety
OT  - mu-receptor antagonist
EDAT- 2019/01/18 06:00
MHDA- 2019/02/08 06:00
CRDT- 2019/01/18 06:00
PHST- 2019/01/18 06:00 [pubmed]
PHST- 2019/02/08 06:00 [medline]
PHST- 2019/01/18 06:00 [entrez]
AID - 10.1080/17512433.2019.1570845 [doi]
PST - ppublish
SO  - Expert Rev Clin Pharmacol. 2019 Feb;12(2):121-128. doi: 
      10.1080/17512433.2019.1570845. Epub 2019 Jan 24.